**Eli Lilly Launches Mounjaro in India: A New Era for Anti-Obesity Treatment**
Eli Lilly & Co., a US pharmaceutical company, has introduced its anti-obesity drug Mounjaro in India, marking the country’s first treatment of this kind. Launched on Thursday, the drug is priced between ₹14,000 and ₹17,500 per month, with specific vial prices set at ₹3,500 for the 2.5mg and ₹4,375 for the 5mg options. Mounjaro, which is administered weekly, is designed to assist in weight loss and manage type-2 diabetes. The company aims to provide competitive pricing in India, where the drug costs approximately $1,000 per month in the US.
### Growing Demand for GLP-1 Drugs
– Mounjaro helps regulate blood sugar, reduces hunger, and slows digestion, promoting a feeling of fullness.
– The drug, known chemically as tirzepatide, activates GIP and GLP-1 hormone receptors.
– The market for GLP-1 drugs is projected to reach $100 billion by 2030, according to Goldman Sachs.
### Competitive Landscape
While Mounjaro has a first-mover advantage in India, it will soon face competition. The rival drug semaglutide (brand name Ozempic) is set to go off-patent in 2026, allowing generics manufacturers like Cipla, Dr. Reddy’s, and others to introduce lower-cost alternatives. Vishal Manchanda from Systematix Group predicts that generics could be priced up to 95% lower than Mounjaro, significantly increasing market volume.
### Implications for Diabetes Patients
Dr. Rajiv Kovil, a senior diabetologist, notes that over 50% of type-2 diabetes patients are overweight. Mounjaro is approved for weight loss in both diabetic and non-diabetic patients, with expectations that usage among diabetic patients will be higher due to greater awareness of treatment options. The Indian Council of Medical Research (ICMR) reports that there are 101 million people with diabetes in India, with at least 40 million on medication. If just 0.5% of these patients use Mounjaro, it could generate sales of $1.5 billion.
**Conclusion**
As Eli Lilly’s Mounjaro enters the Indian market, it opens new avenues for obesity treatment. With the anticipated arrival of generics, how will this impact the accessibility and affordability of weight-loss medications in India?
**FAQ: What is Mounjaro and how does it work?**
Mounjaro is an injectable anti-obesity drug that helps manage blood sugar levels, reduces hunger, and slows digestion, promoting weight loss. It is administered weekly and is approved for use in patients with and without type-2 diabetes.